You are here

COVID-19 Vaccine Workgroup Newsletter


COVID-19 vaccine scheduling

You can now schedule an appointment online to receive a COVID-19 vaccination at a Ballad Health Vaccine Center.

COVID-19 vaccinations are currently only being offered to patients who are aged 65 or older.

Schedule your appointment with your local COVID vaccine center today:


Welcome to the COVID-19 Vaccine Workgroup newsletter page, where you can access all the Workgroup’s newsletters.

Vaccine workgroup

Developments regarding a vaccine for the coronavirus disease 2019 (COVID-19) have been coming at a fast pace, especially since December 2020. But the Ballad Health COVID-19 Vaccine Workgroup has been monitoring vaccine development and planning our regional response for months.

This team consists of physicians and leaders from Ballad Health, regional health departments and East Tennessee State University. To keep our medical professionals informed and updated, the workgroup has provided a series of newsletters addressing vaccine development, approvals, safety and efficacy and distribution.

Workgroup members

Members of the Ballad Health Vaccine Workgroup are Sue Cantrell, MD, Director, Lenowisco and Cumberland Plateau Health Districts; Leigh Johnson, MD MPH, ETSU Health Director of COVID-19 Response; David Kirschke, MD MPH, Northeast Regional Medical Director, Tennessee Department of Health; Stephen May, MD, Sullivan County Regional Health Department; David Reagan, MD PhD, former CMO, Tennessee Department of Health; Clay Runnels, MD, EVP, Chief Physician Executive, Ballad Health; Karen Shelton, MD, Director, Mount Rogers Health District; Jamie Swift, RN, Chief Infection Prevention Officer, Ballad Health; Trish Tanner, Chief Pharmacy Officer, Ballad Health; and Amit Vashist, MD, Chief Clinical Officer, Ballad Health.

Newsletters

Issue #9, Dec. 21, 2020 [PDF]

In this issue:

Summary of the FAQ Internal Analysis of Moderna Vaccine for COVID-19

  • ACIP releases recommendations for use of Moderna COVID-19 vaccine
  • What did the FDA analysts do?
  • What are the primary end points for efficacy and safety?
  • What were the demographics and characteristics of study populations?
  • What were the key findings for efficacy?
  • What were the key findings for safety?
  • What questions remain?
  • Conclusions

Issue #8, Dec. 15, 2020 [PDF]

In this issue:

  • Myths and facts about the new COVID-19 vaccine

Issue #7, Dec. 15, 2020 [PDF]

In this issue:

  • FAQ from the ACIP meeting on Dec. 12, 2020, on the Pfizer COVID-19 vaccine

Issue #6, Dec. 14, 2020 [PDF]

In this issue:

Summary of Internal Analysis of Pfizer/BioNTech Vaccine for COVID-19

  • What did the FDA analysis do?
  • What are the primary end points for efficacy and safety?
  • What were the demographics and characteristics of the study population?
  • What were the key findings for efficacy?
  • What were the key findings for safety?
  • What questions remain?

Issue #5, Dec. 7, 2020 [PDF]

In this issue:

  • An interview with Dr. David Kirschke

  • Updated COVID-19 vaccine FAQ

Issue #4, Nov. 25 [PDF]

In this issue:

  • How will federally purchased vaccines be available?
  • Vaccine allocation and distribution

Issue #3, Nov. 19 [PDF]

In this issue:

A look at the leading vaccine candidates

  • Pfizer/BioNTech/Fosun Pharma
  • Moderna
  • Johnson & Johnson
  • AstraZeneca
  • Novavax

Issue #2, Nov. 17 [PDF]

In this issue:

  • How are vaccines approved by the government?

  • How and when will a COVID-19 vaccine get approval?
  • How are the ACIP and CDC involved in the process?

Issue #1, Nov. 13 [PDF]

In this issue:

  • Vaccine development process

  • How do we know a new vaccine is safe?
  • How do we know a new vaccine is effective?